Niagen Competitors
| NAGE Stock | 6.01 0.27 4.30% |
Niagen Bioscience vs Kalvista Pharmaceuticals Correlation
Pay attention - limited upside
The correlation between Niagen Bioscience and KALV is -0.78 (i.e., Pay attention - limited upside) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Niagen Bioscience and KALV in the same portfolio, assuming nothing else is changed.
Moving against Niagen Stock
| 0.78 | SBSW | Sibanye Gold | PairCorr |
| 0.78 | MARUF | Marubeni | PairCorr |
| 0.75 | COCSF | Coca Cola FEMSA | PairCorr |
| 0.68 | WAT | Waters | PairCorr |
| 0.6 | RVTY | Revvity Earnings Call This Week | PairCorr |
Niagen Bioscience Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Niagen Bioscience and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Niagen and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Niagen Bioscience does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Niagen Stock performing well and Niagen Bioscience Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Niagen Bioscience's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| OLMA | 6.27 | 2.81 | 0.67 | (0.69) | 2.77 | 9.82 | 145.73 | |||
| CRVS | 6.44 | 3.46 | 0.75 | (0.35) | 2.61 | 9.63 | 167.61 | |||
| PRTA | 2.31 | (0.12) | 0.00 | (0.01) | 0.00 | 5.10 | 12.28 | |||
| VTYX | 6.07 | 2.49 | 0.46 | 9.32 | 3.58 | 14.60 | 86.34 | |||
| KROS | 2.14 | 0.31 | 0.10 | 1.07 | 2.24 | 5.33 | 20.93 | |||
| AKBA | 3.49 | (1.11) | 0.00 | (0.67) | 0.00 | 5.24 | 36.66 | |||
| RIGL | 3.91 | 0.37 | 0.09 | 0.35 | 3.80 | 8.66 | 44.65 | |||
| ZVRA | 2.13 | (0.30) | 0.00 | (0.89) | 0.00 | 4.43 | 14.16 | |||
| RGNX | 3.26 | 0.04 | 0.02 | 0.09 | 4.24 | 7.94 | 23.68 | |||
| KALV | 3.15 | 0.39 | 0.11 | 0.37 | 3.21 | 8.43 | 25.15 |
Cross Equities Net Income Analysis
Compare Niagen Bioscience and related stocks such as Olema Pharmaceuticals, Corvus Pharmaceuticals, and Prothena plc Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OLMA | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (4.3 M) | (22.1 M) | (71.1 M) | (102.6 M) | (96.7 M) | (129.5 M) | (116.5 M) | (110.7 M) |
| CRVS | (176 K) | (176 K) | (176 K) | (176 K) | (176 K) | (31.3 M) | (36.4 M) | (55.7 M) | (46.9 M) | (43.7 M) | (4.8 M) | (43.2 M) | (41.3 M) | (27 M) | (62.3 M) | (56.1 M) | (58.9 M) |
| PRTA | (12.5 M) | (29.7 M) | (41.4 M) | (41 M) | (7.2 M) | (80.6 M) | (160.1 M) | (153.2 M) | (155.6 M) | (77.7 M) | (111.1 M) | 67 M | (116.9 M) | (147 M) | (122.3 M) | (110.1 M) | (115.6 M) |
| VTYX | (4.5 M) | (4.5 M) | (4.5 M) | (4.5 M) | (4.5 M) | (4.5 M) | (4.5 M) | (4.5 M) | (4.5 M) | (4.5 M) | (28.2 M) | (83.7 M) | (108.4 M) | (193 M) | (135.1 M) | (121.6 M) | (127.7 M) |
| KROS | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (12.3 M) | (45.4 M) | (58.7 M) | (104.7 M) | (153 M) | (187.4 M) | (168.6 M) | (160.2 M) |
| AKBA | (8.2 M) | (8.2 M) | (8.2 M) | (13.2 M) | (37 M) | (60.7 M) | (135.7 M) | (76.9 M) | (171.9 M) | (279.7 M) | (349.9 M) | (244.9 M) | (94.2 M) | (51.9 M) | (69.4 M) | (62.5 M) | (65.6 M) |
| RIGL | (12.4 M) | (86 M) | (98.8 M) | (89 M) | (90.9 M) | (51.5 M) | (69.2 M) | (78 M) | (70.5 M) | (66.5 M) | (29.7 M) | (17.9 M) | (58.6 M) | (25.1 M) | 17.5 M | 15.7 M | 16.5 M |
| ZVRA | (70.4 K) | (70.4 K) | (70.4 K) | (5.2 M) | (24.5 M) | (54.7 M) | (16.5 M) | (43.4 M) | (56.5 M) | (24.5 M) | (12.8 M) | (8.6 M) | (26.8 M) | (46 M) | (105.5 M) | (95 M) | (90.2 M) |
| RGNX | (5.4 M) | (5.4 M) | (5.4 M) | (5.4 M) | (4 M) | (22.8 M) | (63 M) | (73.2 M) | 99.9 M | (94.7 M) | (111.2 M) | 127.8 M | (280.3 M) | (263.5 M) | (227.1 M) | (204.4 M) | (194.2 M) |
| KALV | (2.1 M) | (2.1 M) | (2.1 M) | (5.7 M) | (13.4 M) | (24.8 M) | (18.6 M) | (15.8 M) | (20.8 M) | (29.1 M) | (46.2 M) | (82.3 M) | (92.9 M) | (126.6 M) | (183.4 M) | (24.8 M) | (26.1 M) |
Niagen Bioscience and related stocks such as Olema Pharmaceuticals, Corvus Pharmaceuticals, and Prothena plc Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Niagen Bioscience financial statement analysis. It represents the amount of money remaining after all of Niagen Bioscience operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Niagen Bioscience Competitive Analysis
The better you understand Niagen Bioscience competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Niagen Bioscience's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Niagen Bioscience's competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Niagen Bioscience Competition Performance Charts
Five steps to successful analysis of Niagen Bioscience Competition
Niagen Bioscience's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Niagen Bioscience in relation to its competition. Niagen Bioscience's competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Niagen Bioscience in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Niagen Bioscience's competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Niagen Bioscience, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Niagen Bioscience position
In addition to having Niagen Bioscience in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Macroaxis Picks Thematic Idea Now
Macroaxis Picks
Daily selected watch list of stocks of large companies handpicked by Macroaxis Team based on their diversification potential. The Macroaxis Picks theme has 47 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Macroaxis Picks Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Niagen Bioscience Correlation with its peers. For information on how to trade Niagen Stock refer to our How to Trade Niagen Stock guide.You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Niagen Bioscience. If investors know Niagen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Niagen Bioscience listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.5 | Earnings Share 0.24 | Revenue Per Share | Quarterly Revenue Growth 0.329 | Return On Assets |
The market value of Niagen Bioscience is measured differently than its book value, which is the value of Niagen that is recorded on the company's balance sheet. Investors also form their own opinion of Niagen Bioscience's value that differs from its market value or its book value, called intrinsic value, which is Niagen Bioscience's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Niagen Bioscience's market value can be influenced by many factors that don't directly affect Niagen Bioscience's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Niagen Bioscience's value and its price as these two are different measures arrived at by different means. Investors typically determine if Niagen Bioscience is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Niagen Bioscience's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.